Enzyme News: Breaking Enzyme News, Comments and Articles. - Page: 3

BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform for Screening Kinases and Methyltransferases

Madison WI (PRWEB) May 10, 2013 Join us for a webinar on May 15, 2013 at 12:00 PM EDT. An Integrated instrument-Reagent Platform for Screening and Profiling Kinases and Methyltransferases Register now! https://attendee.gotowebinar.com/regi...

NEB Releases a New Site-Directed Mutagenesis Kit for Both Standard and Novel Uses, Including Long Insertions and Deletions

IPSWICH, Mass., May 10, 2013 /PRNewswire/ -- New England Biolabs (NEB), a world leader in the discovery and production of reagents for the life science industry, launched a new reagent kit for site-directed mutagenesis (SDM). The Q5® Site-Directed Mutagenesis Kit (Q5 SDM Kit) is capable of introducing long insertions and deletions, thus allowing a broader range of applications for this widely...

Biotie announces start of clinical study with nepicastat (SYN117) in cocaine dependence

BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE     10 May 2013 at 9.00 a.m. Biotie announces start of clinical study with nepicastat (SYN117) in cocaine dependence Biotie Therapies today announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in cocaine dependence. The National Institute on Drug Abuse (NIDA) at the US National Institutes of Health is funding the con...

Children born with CDG don't contain mutation in every cell type, say Sanford-Burnham researchers

Children born with rare, inherited conditions known as Congenital Disorders of Glycosylation, or CDG, have mutations in one of the many enzymes the body uses to decorate its proteins and cells with sugars.

Creative BioMart Funded Research Found Another Anticancer Strategy - Targeting Cyclin D

New York, NY, May 10, 2013 --(PR.com)-- One of the researchers said, “Blocking cyclin D represents a highly selective anticancer strategy that specifically targets cancer cells without significantly affecting normal tissues." In what is seen as a promising and highly selective treatment strategy, scientists have safely shut down breast cancer and a form of leukemia in mice by targetin...

Pyruvate Kinase M2 Activators for the Treatment of Cancer

This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate of nucleic acid synthesis, including most tumor...

With Doping Cloud Lifted, BuckPower Deer Antler Velvet Sales up 84% at GNC Retail Stores

Sales skyrocket as Vijay Singh saga continues With professional athletes use of deer antler velvet as a performance enhancement supplement again in the spotlight, more consumers are rushing to try BuckPower. TCCD International reports sales of its product BuckPower Deer Antler Velvet at GNC stores nationwide were up 84% over the previous week....

Verenium Reports Financial Results For The First Quarter Ended March 31, 2013

SAN DIEGO, May 9, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported financial results for the first quarter ended March 31, 2013, and also provided full year 2013 financial guidance. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)...

BioCryst to Present at Two Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the following investor conferences: Bank of America Merrill Lynch Healthcare Conf

Metabolism and Environmental Degradation Studies Come Under Scrutiny at New International Conference

Leatherhead, 9 May:  Smithers Viscient’s inaugural conference ‘Advances in Metabolism & Environmental Degradation Science’ will put the spotlight on current practice in the metabolism and degradation studies that form the basis of almost every pesticide registration data package filed today.  Taking place in Dusseldorf on 5-6 June, the conference gives regulator...

Synageva BioPharma™ Announces One Year of Treatment Data with Sebelipase Alfa in Late Onset LAL Deficiency

-Sebelipase alfa effects sustained and treatment generally well tolerated- Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today reported 12-month results from an ongoing extension study with sebelipase alfa in adults with late onset Lysosomal Acid Lipase (LAL)...

Acorda Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Andrew R. Blight, Ph.D., Acorda’s Chief Scientific Officer will present at the Bank of America Merrill Lynch 2013 Health Care Conference on Thursday, May 16 at 10:40 a.m. at the Encore at the Wynn Las Vegas Hotel in Las Vegas, Nevada. A live audio webcast of the presentation can be ac...

DNA replication: Driving past four-stranded snags

Unusual DNA structures, such as G-quadruplexes, can stall DNA replication with drastic consequences for the cell. The Pif1 helicase family of enzymes has evolved to disentangle these structures efficiently.

Cornerstone Therapeutics Acquires Exclusive U.S. Marketing Rights to PERTZYE(R) (pancrelipase) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis

CARY, NC -- (Marketwired) -- 05/09/13 -- Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, today announced it has entered into an agreement with Digestive Care, Inc. (DCI) to acquire exclusive U.S. rights to market PERTZYE® (pancrelipase) for the treatment of Exocrine Pancreatic In...

New advance in biofuel production

(DOE/Lawrence Berkeley National Laboratory) Joint BioEnergy Institute researchers have developed an enzyme-free ionic liquid pretreatment of cellulosic biomass that makes it easier to recover fermentable sugars for biofuels and to recycle the ionic l...

Halozyme Reports First Quarter 2013 Financial Results

SAN DIEGO, May 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) "With the potential for 3 new product launches over the next 12 months and continued progress on the Hylenex® brand, I am pleased with the steps we are making towards our...

New England Biolabs Releases the NEBNext Microbiome DNA Enrichment Kit

IPSWICH, Mass., May 8, 2013 /PRNewswire/ -- New England Biolabs (NEB) announces the release of the NEBNext® Microbiome DNA Enrichment Kit, which uses a novel method to separate microbial DNA from host DNA, thereby reducing the high cost of sequencing microbiome DNA to a more practical level. (Logo:  http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b ) Microbiome samples are...

Nimbus Discovery Announces Agreement with Shire to Co-Develop Therapies for Rare Diseases

Companies Enter Agreement to Co-Develop First-in-Class Small Molecule Therapies for Key Lysosomal Storage Disorders Nimbus Discovery, LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible disease targets, today announced a co-development agreement with Shire plc focused on small molecule treatments for se...

High Response to Enzyme in Peyronie's (CME/CE)

SAN DIEGO (MedPage Today) -- An injectable enzyme produced significant reductions in scar tissue and penile curvature without surgery in patients with Peyronie's disease, according to a large randomized trial.

GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research

IRVINE, Calif., May 8, 2013 /PRNewswire/ -- GeneTex, Inc., a leading manufacturer of antibodies and antibody-related reagents, is introducing a new mouse monoclonal antibody to the human Ten-Eleven Translocation 1 (TET1) protein. The discovery in 2009 (Tahiliani et al, 2009) that this enzyme can convert the DNA methylation mark 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) helped t...

Dyadic International To Announce First Quarter 2013 Financial Results And Host Conference Call On Wednesday, May 15, 2013

JUPITER, Fla., May 8, 2013 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company, today announced that it will report its financial results for the first quarter ended March 31, 2013 after market close on Wednesday, May 15, 2013 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. (Logo:  http://photos.prnewswire.c...

Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"

SAN DIEGO, May 8, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it will present analysis methods for  the MYDICAR development program at an upcoming Conference. The conference "Statisticians in the Pharmaceutical Industry International Conference"...

Gene offers clues to new treatments for a harmful blood clotting disorder

(Medical Xpress)—A gene associated with both protection against bacterial infection and excessive blood clotting could offer new insights into treatment strategies for deep-vein thrombosis—the formation of a harmful clot in a deep vein. The gene...

Portola Announces Its Factor Xa Inhibitor Antidote PRT4445 Produces Rapid, Sustained and Dose-Related Reversal of the Anticoagulant Activity of Eliquis(R) in Phase 2 Study

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/08/13 -- Portola Pharmaceuticals, Inc. today announced efficacy and safety data from the Phase 2 proof-of-concept study of PRT4445 in healthy volunteers who were administered the Factor Xa inhibitor Eliquis® (apixaban). Analysis of anticoagulation markers and plasma concentration levels of Eliquis in blood samples taken from the subjects indicates t...

Celsus Therapeutics Announces Positive Phase II Interim Results for MRX-6 in the Treatment of Contact Dermatitis

NEW YORK, NY and LONDON -- (Marketwired) -- 05/08/13 -- Celsus Therapeutics (OTCQB: MRRBY), an emerging growth, development-stage biotechnology company, announced today positive interim results from the first cohort (2% MRX-6 vs. vehicle) of a multi-center Phase II double blind, two step dose-ranging, vehicle and active control study of MRX-6 for the treatment of patients with allergic contact de...